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Nonsteroidal anti-inﬂammatory drugs (NSAIDs) are commonly used in bone tissue repair treatment for their pharmacological
action. The objective of this study was to determine the eﬀect of aspirin, on osteoblast growth, using MG63 cell line as osteoblast
model. MTT spectrophotometry results showed that 20, 100, and 1000μM aspirin doses have an inhibitory eﬀect on growth. Cell
cycle analysis revealed that aspirin doses of 100 and 1000μM arrest the cell cycle in phase GO/G1. Parallel apoptosis/necrosis
studies showed no changes in comparison to control cells after treatment with 1 or 10μM aspirin but a signiﬁcantly increased
percentage of cells in apoptosis at doses of 20, 100, and 1000μM. We highlight that treatment of osteoblast-like cells with 1000μM
aspirin increased not only the percentage of cells in apoptosis but also the percentage of necrotic cells, which was not observed in
aspirin treatments at lower doses.
1.Introduction
Nonsteroidal anti-inﬂammatory drugs (NSAIDs) are widely
used in orthopaedic surgery and traumatology to reduce
pain and inﬂammation. Animal and cell culture studies have
shown that some NSAIDs have an adverse eﬀect on bone
tissue through regeneration delay [1–6].
The mechanism by which NSAIDs exert their action on
cell growth is under debate. Some authors cite the capacity
of NSAIDs to inhibit synthesis of prostaglandin (PG), a
molecule that is synthesized by osteoblasts and autocrinally
favours their growth [7, 8]. Others propose that the drug has
a direct eﬀect on the cell cycle based on in vitro ﬁndings that
therapeutic doses of ketorolac, indomethacin, or diclofenac
induce cell death in osteoblast cultures from rat foetal
calvaria and may suppress bone formation and impair bone
remodelling by arresting cell cycle in phase G0/G1 [9, 10].
Diﬀerent NSAIDs were recently reported to aﬀect
osteoblast proliferative capacity and modulate other features
of this cell population, including diﬀerentiation, antigenic
proﬁle, and phagocytic capacity [11, 12]. However, Arporn-
maeklong et al. [13] found that indomethacin and celecoxib
inhibit cell growth but have a less clear eﬀect on cell
diﬀerentiation as determined by alkaline phosphatase and
osteocalcin synthesis.
Acetylsalicylic acid (aspirin) is very frequently adminis-
tered for its anti-inﬂammatory, antipyretic, antiaggregant,
and analgesic properties. However, in contrast to other
NSAIDs, few data are available on its eﬀects on bone tissue
or on osteoblasts, the cells responsible for bone formation
and regeneration. Therefore, the objective of this study was
to analyse the eﬀect of aspirin at diﬀerent doses on osteoblast
cell growth, using the human MG63 osteosarcoma cell line.
2.MaterialsandMethods
2.1. Cell Culture. The human MG-63 osteosarcoma cell line
was purchased from American Type Cultures Collection
(ATCC, Manassas, VA) and maintained as described by
D´ ıaz-Rodr´ ıguez et al. [14] in Dulbecco’s-modiﬁed Eagle
medium (DMEM; Invitrogen Gibco Cell Culture Products,
Carlsbad, CA) with 100IU/mL penicillin (Lab Roger SA,
Barcelona,Spain),50μg/mLgentamicin(BraumMedicalSA,
Jaen, Spain), 2.5μg/mL amphotericin B (Sigma, St Louis,2 The Scientiﬁc World Journal
MO, USA), 1% glutamine (Sigma, St Louis, MO, USA), and
2% HEPES (Sigma), supplemented with 10% foetal bovine
serum (FBS) (Gibco, Paisley, UK). Cultures were kept at
37◦C in a humidiﬁed atmosphere of 95% air and 5% CO2.
Cells were detached from the culture ﬂask with a solution
of 0.05% trypsin (Sigma) and 0.02% ethylene diamine tetra-
acetic acid (EDTA) (Sigma) and then washed and suspended
in complete culture medium with 10% FBS.
2.2. Cell Proliferation. Cell proliferation was determined by
the MTT method. Osteoblasts were seeded at 1 × 104
cells/mL per well into a 96-well plate without FBS and
cultured at 37◦C for 24 hours. Subsequently, the medium
was replaced with DMEM containing aspirin at a dose of 0,
0.1, 1, 10, 20, 100, or 1000μM. At the end of treatments, the
medium was replaced with DMEM containing 0.5mg/mL
MTT (Sigma) and incubated for 4 hours. Cellular reduction
of the MTT tetrazolium ring resulted in the formation of
a dark-purple water-insoluble deposit of formazan crystals.
After incubation, the medium was aspirated and DMSO
was added to dissolve the formazan crystals. Absorbance
was measured at 570nm with a spectrophotometer (Sunrise,
Tecan, M¨ annedorf, Switzerland).
2.3. Cell Cycle. Cultured human MG-63 osteosarcoma cells
treated with 1, 10, 20, 100, or 1000μM of aspirin and
untreated control cells were detached from the culture ﬂask
by treatment with a solution of 0.05% trypsin (Sigma)
and 0.02% EDTA (Sigma) and subsequently washed, and
suspended in PBS and prepared for the study of cell cycle
as reported by Garc´ ıa-Mart´ ınez et al. [15]. The suspension
obtained was placed in 200μL PBS with 2mL ice-cold
70% ethanol and 30% distilled H2O and then vigorously
mixed. Cells were left for at least 30min. in the cold
and then harvested by centrifugation and resuspended in
800μL PBS. Cells were microscopically examined and, if
clumped, passed through a 25-gauge syringe needle. Cells
were then incubated at 37◦C for 30min. with 100μLr i b o n u -
clease (RNase) (1mg/mL) and 100μL propidium iodide
(PI). Finally, samples were analyzed by using an argon-ion
laser tuned to 488nm (Fasc Vantage Becton Dickinson),
measuring forward and orthogonal light scatter and red
ﬂuorescence, determining both area and Esther peak of the
ﬂuorescent signal.
2.4. Apoptosis and Necrosis Analysis. Cultured human MG-
63 osteosarcoma cells treated with 1, 10, 20, 100, or 1000μM
aspirin for 12h and untreated control cells were detached
from the culture ﬂask, washed and suspended in 300μL PBS
and then labelled with annexin V and PI (Immunostep S.L.,
Salamanca, Spain). We incubated 100μL aliquots of the cell
suspension with 5μL annexin V and 5μL PI for 30min. at
4◦C in the dark. Cells were then washed, suspended in 1mL
PBS, and immediately analyzed in a ﬂow cytometer with
argon laser (Fasc Vantage Becton Dickinson, Palo Alto, CA)
at a wavelength of 488nm to determine the percentage of
ﬂuorescent cells. Given that negative and positive controls
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Figure 1: Eﬀects of diﬀerent aspirin doses (0.1μM, 1μM, 10μM,
20μM, 100μM, or 1000μM) on osteoblast proliferation in MG-63
cell line after 24h of incubation. Data are expressed as means +
SEM. We compared data between each treatment and control
culture by analysis of variance (ANOVA) test. ∗P = 0.023, ∗∗P =
0.014, ∗∗∗P = 0.001.
were included, we calculated the percentage of annexin-
positive(apoptotic)cellsandPI-positive(necrotic)cellsfrom
2000–3000 cell counts.
2.5. Statistical Analysis. R software (version 2.9.2, Auckland,
New Zealand) was used for data analysis. Mean values
(±standard deviation) were calculated for each variable. A
two-way repeated-measures analysis of variance (ANOVA)
was performed to examine the eﬀects on proliferation,
cell cycle, and apoptosis/necrosis induction, considering
treatment (aspirin), time (24h), and concentration (0.1, 1,
10, 20, 100, or 1000μM). When a signiﬁcant interaction was
identiﬁed,theBonferronicorrectionwasappliedforplanned
pair-wise comparisons. P<0.05 was considered signiﬁ-
cant. At least three experiments were performed for each
culture.
3. Results
3.1. Eﬀect of Aspirin Treatment on Mg-63 Cell Line Prolifera-
tion. NosigniﬁcanteﬀectonMG-63proliferation(P>0.05)
was observed after 24h treatment at any of the assayed doses
(0.1, 1, and 10μM aspirin). However, signiﬁcant adverse
eﬀect on cell growth was observed after treatment for 24h
at aspirin doses of 20μM( P = 0.014), 100μM( P = 0.023),
and 1000μM( P = 0.001) (Figure 1).
3.2. Cell Cycle Study. The percentage of cells in each cell
cycle phase (G0/G1, G2/M and S) was determined by ﬂow
cytometry. Table 1 and Figure 2 depict the results of the cell
cycle study. No signiﬁcant eﬀect on MG-63 cell cycle (P>
0.05) was observed after treatment for 24h with 1, 10, or
20μMdosesofaspirin.However,thecellpercentageinG0/G1
phasewassigniﬁcantlyincreasedbytreatmentatdosesof100
and 1000μM( P< 0.001). The mean percentage cell count
in G0/G1 phase was 42.68 in control cultures versus 54.38 in
100μM-treated and 77.44 in 1000μM-treated cultures.The Scientiﬁc World Journal 3
Table 1: Numerical data for cell cycle ﬂuorescence proﬁle of MG-63 cells in culture treated for 24 h with aspirin doses of 1, 10, 20, 100, or
1000μM.
G0-G1 G2-M S
Mean P value Mean P value Mean P value
Control 44.34 (2.79) — 27.22 (0.57) — 30.09 (0.07) —
Aspirin 1μM 42.34 (2.63) 0.46 26.41 (2.26) 0.58 31.02 (0.41) 0.07
Aspirin 10μM 42.21 (5.25) 0.5 24.85 (3.74) 0.3 32.94 (2.48) 0.1
Aspirin 20μM 41.54 (2.16) 0.24 27.52 (0.60) 0.57 30.93 (1.75) 0.47
Aspirin 100μM 54.38(1.79) 0.006∗ 20.94 (1.35) 0.002∗ 24.68 (2.96) 0.03
Aspirin 1000μM 77.44 (0.83) 0.0001∗ 5.95 (1.15) 0.0001∗ 16.60 (1.93) 0.0001∗
∗Signiﬁcant diﬀerences.
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Figure 2: Eﬀects of aspirin on cell cycle kinetics of MG-63 cell
line determined by ﬂow cytometry. Cultured cells were treated for
24h with 1, 10, 20, 100, or 1000μM aspirin. Control group was
not treated. G0/G1, S, and G2/M represent the percentage of cells
distributed among these phases after treatment, as determined by
ﬂow cytometry. We repeated experiments at least three times.
3.3. Apoptosis. Annexin V and PI were used to further dis-
criminate apoptotic cell death from necrotic cell death in
the cell cycle. Table 2 and Figure 3 show results of one
experimentafterculturefor12h,asanexample.Thenumber
of viable cells (Ann V−,P I −) was counted in the lower
left quadrant (Q3) of density plots, and the percentages of
cells in early apoptosis (Ann V+,P I −,l o w e rr i g h tq u a d r a n t
Q4), late apoptosis (Ann V+,P I +,u p p e rr i g h tq u a d r a n t
Q2), and necrosis (Ann V−,P I +, upper left quadrant Q1)
were determined. Figure 3 shows the cell percentage in each
quadrant after 12h exposure to aspirin at diﬀerent doses.
No signiﬁcant eﬀect was found on the cell percentage in any
quadrant after treatment for 12h at doses of 1 and 10μM
aspirin. In contrast, a signiﬁcant increase in cell percentage
was observed versus controls in early apoptosis (8.31 versus
3.71%, P = 0.043) and late apoptosis (14.69 versus 2.84%,
(P<0.001) after 12 h treatment with a 20μM dose, ﬁnding
a signiﬁcant reduction in living cells in the treated group
versus controls (69.59% versus 89.82%, P = 0.012). After
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Figure 3: Percentage of Annexin V binding and propidium iodide
uptake of MG63 cells after culture for 12h. Q1 (necrosis: Ann V−,
PI+), Q2 (late apoptosis: Ann V+,P I +), Q3 (viable cells: Ann V−,
PI−), and Q4 (early apoptosis: Ann V+,P I −). Data are means ±
standard deviation of at least three independent determinations.
12 h treatment with 100μM aspirin, the cell percentage in
early apoptosis increased by 13.74% (P = 0.002 versus
controls) and the percentage in late apoptosis by 13.18%
(P = 0.0092 versus controls) and there was a reduction of
67.61% in living cells (P = 0.001 versus controls). After 12
h treatment with 1000μM aspirin, cell percentage in early
apoptosis increased by 13.82% (P = 0.001 versus controls),
the percentage in late apoptosis increased by 13.18% (P =
0.0092), and the percentage of necrotic cells increased by
11.81% (P = 0.001), and there was a 65.41% decrease in
living cells (P = 0.002).
4. Discussion
The anti-inﬂammatory properties of NSAIDs, including
aspirin, derive from their powerful inhibitory eﬀects on
cyclooxygenase metabolites such as prostaglandin E2 [16].
Consequently, some authors attribute the adverse eﬀect4 The Scientiﬁc World Journal
Table 2: Numerical data for the percentage annexin V binding and propidium iodide uptake of MG63 cells after culture for 12 h. Q1
(necrosis: Ann V−,P I +), Q2 (late apoptosis: Ann V+,P I +), Q3 (viable cells: Ann V−,P I −), Q4 (early apoptosis: Ann V+ PI−). Data are
means ± standard derivation of at least three independent determinations.
MEAN SD P C.I. (95%)
Control
Necrosis 3.61 1.6163 — —
Late Ap. 2.84 1.4530 — —
Negative 89.82 4.2866 — —
Apoptosis 3.71 1.9480 — —
A1μM
Necrosis 9.31 0.5695 0.005 −8.4471; −2.9528
Late Ap. 8.16 0.4923 0.004 −7.7793; −2.8606
Negative 73.09 0.3157 0.021 6.1649; 27.3016
Apoptosis 9.42 0.3005 0.007 −8.8695; −2.5504
A10μM
Necrosis 5.97 0.5697 0.076 −5.1072; 0.3872
Late Ap. 1.3467 0.2514 0.213 −1.9720; 4.9720
Negative 90.0267 1.3050 0.941 −7.3861; 6.9794
Apoptosis 2.6533 0.6192 0.421 −2.2166; 4.3332
A20μM
Necrosis 5.64 1.4516 0.182 −5.5058; 1.4592
Late Ap. 14.69 0.4531 0.000 −14.2832; −9.4034
Negative 69.59 0.8826 0.012 10.1319; 30.3281
Apoptosis 8.31 1.8938 0.043 −8.9583; −0.2482
A100μM
Necrosis 5.48 1.4807 0.215 −5.3772; 1.6505
Late Ap. 13.18 2.1219 0.002 −14.4558; −6.2108
Negative 67.61 2.3404 0.001 14.3844; 30.0422
Apoptosis 13.74 3.0390 0.009 −15.8230; −4.2502
A1000μM
Necrosis 11.81 1.5383 0.003 −11.7735; −4.6197
Late Ap. 8.94 3.2706 0.042 −11.8335; −0.3597
Negative 65.41 3.5840 0.002 15.4499; 33.3633
Apoptosis 13.82 1.0186 0.001 −13.6404; −6.5929
of NSAIDs on osteoblasts to a reduced synthesis of
prostaglandins, which act as bone cell growth factors, as
a result of the inhibition of cyclooxygenase enzymes [17].
However, there is some controversy concerning the adverse
eﬀectofNSAIDsonosteoblastgrowth[10,18].Thedisparate
results obtained may be due to multiple factors, including
dosage, treatment duration, and the species in question
[13, 17].
In this study, the proliferative capacity of cells from
the MG-63 cell line was not signiﬁcantly inhibited by 24 h
treatment with 0.1, 1, or 10μM aspirin but was signiﬁcantly
inhibited by 24 h treatment with 20, 100, and 1000μM
aspirin. Therefore, this NSAID does not have an adverse
eﬀect on bone cell proliferation in vitro at the therapeutic
dose range used in the clinical setting (1 to 10μM). It was
previouslyreported thatthe dose of NSAIDs is akey factorin
theeﬀectoncellproliferationaswellasoncelldiﬀerentiation
and migration [19].
The eﬀect of diﬀerent doses on the growth of the MG63
line is closely related to the eﬀects observed on the cell cycle.
Thus, the negative eﬀect on growth at 100 and 1000μM
aspirin may be explained by the signiﬁcant increase in
the percentage of cells in phase G0/G1 versus the control
group. Ann V and PI staining showed that the reduced cell
growth at 20 and 100μM doses was attributable to apoptosis
rather than necrosis. In contrast, treatment with a 1000μM
produced an increase in necrotic cells as well as cells in
apoptosis.
We highlight that treatment of the MG63 line with
therapeutic doses of aspirin (1–10μM) did not cause cell
death, cell cycle changes, or modiﬁcations in apopto-
sis/necrosis induction. In contrast, therapeutic doses of
ketorolac, indomethacin, or diclofenac induced cell death in
osteoblast cultures from rat foetal calvaria and may suppress
bone formation and impair bone remodelling by cell cycle
arrest in G0/G1 phase [9, 10]. In another in vitro study, 24
h treatment with indomethacin or nimesulide at therapeutic
doses also reduced osteoblast growth capacity and produced
signiﬁcant changes in the cell cycle, which was again arrested
in G0/G1 phase [12].
A recent cohort study of subjects exposed and not
exposed to NSAIDs and opioids observed no diﬀerence in
bone mineral density over time but reported excessive risk
of fractures in users of some NSAIDs, although not in those
receiving aspirin [20]. These results are consistent with the
present in vitro data.
Furthermore, another important aspect of aspirin, from
a clinical standpoint, is that when the lipoxin pathwayThe Scientiﬁc World Journal 5
is activated in the presence of aspirin, acetylation of the
cyclooxygenase 2 enzyme present at inﬂammation sites
not only inhibits further production of prostanoids, but
also induces the synthesis of 15-hydroxyeicosatetraenoic
acid, which is then transformed into 5(S)-epoxytetraene
in leukocytes in the presence of 5-lipoxygenase. The 5(S)-
epoxytetraene intermediate is then transformed to 15-
epilipoxins or aspirin-triggered lipoxins, which are more
b i o a c t i v et h a nn a t i v el i p o x i n sa n dh a v em o r ep o w e r f u l
resolving properties [21, 22].
In conclusion, aspirin at therapeutic doses appears to
have no adverse eﬀect on osteoblast growth, unlike some
other NSAIDs. Growth was only reduced at higher doses,
by cell cycle arrest and apoptosis induction. These ﬁndings
support the use of aspirin in the treatment of inﬂammation
and pain in bone lesions requiring tissue regeneration. Given
reports that indomethacin and diclofenac can increase cell
adhesion and reduce the migration of diﬀerent cell popu-
lations [23–25], further research is warranted to determine
whether aspirin may exert action on the cell adhesion or
migration of osteoblasts, other key factors in the regenerative
process.
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